All In Biotech

Drug Trial Radar · NCT05321147

Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2

A Multi-center Phase Ib Trial Evaluating the Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2

Last checked: Nov 19, 2026Latest source record: Mar 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Mar 17, 2022

Primary completion

Nov 19, 2023

Study completion Feb 8, 2024

Sponsor

Lead sponsor
Innate PharmaIndustry
Sponsor type
Industry
First posted
Apr 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center phase Ib study, which evaluates the safety and efficacy of lacutamab monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma that express KIR3DL2.

Conditions

  • Peripheral T Cell Lymphoma

Interventions

  • lacutamabBiological

    Patients will receive a fixed dose of 750mg as 1-hour IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of adverse events (AEs)Time frame: From consent is obtained until EOT visit (28 days after the last administration of study drug lacutamab)

Locations

20 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham- O'Neal Comprehensive Cancer Center

    Birmingham, Alabama

  • University of California at Irvine - Chao Family Comprehensive Cancer Center

    Orange, California

  • Goshen Health- Goshen Hospital

    Goshen, Indiana

  • Indiana University School of Medicine

    Indianapolis, Indiana

  • University of Iowa

    Iowa City, Iowa

  • University of Maryland

    Baltimore, Maryland

  • Memorial Sloan Kettering Cancer Center- David H. Koch Center for Cancer Care

    New York, New York

  • Allegheny Health

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina - Health Hollings Cancer Center

    Charleston, South Carolina

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Inje University Busan Paik Hospital

    Busan, South Korea

  • Chungnam National University Hospital

    Daejeon, South Korea

  • Seoul National University Bundang Hospital

    Gyeonggi-do, South Korea

  • Gachon University Gil Medical Center

    Incheon, South Korea

  • The Catholic University of Korea, Yeouido St. Mary's Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Korea University Anam Hospital

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital Yonsei University Health System

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.